tgindex
IPO Watch

Leading IPO Portal In India.

Последний пост
03:49
Последнее чтение
01:11
Постов за неделю
49
Всего постов
1 081
Тип
открытый
Язык
английский
Категория
Новости и СМИ (по похожим)
В каталоге с
13 авг.
Подписчики
2 222
+51 за 5 дн.
Сутки
+13
+0,59%
Неделя
 
Месяц
 
Просмотров на пост
602
40 постов
Вовлечённость
27,1%
к подписчикам
Постов в день
7,0
всего 1 081
Упоминаний
0
каналов
Охват размещения
оценка
1/24сутки в ленте
437
1/48двое суток
500
1/72трое суток
540

Оценка по просмотрам недавних постов: пост набирает почти всё за первые сутки.

Посты

  • 🚨 SYMBIOTEC PHARMALAB – PRE-IPO SECONDARY SALE UPDATE 💰📊 ₹841.41 MILLION WORTH OF SHARES TRANSFERRED ON 17 AUGUST 2026 🔥 Symbiotec Pharmalab Limited has disclosed multiple secondary-sale/pre-IPO share transactions involving its existing shareholders and investors. 📅 Transaction Date: 17 August 2026 💰 KEY TRANSACTIONS 🔹 Ani Satwani ➝ Motilal Oswal India Excellence Fund – Mid to Mega Series II 📌 Shares: 3,40,000 💵 Price: ₹988/share 💰 Transaction Value: ₹335.92 Million 🔹 Satwani Holdings LLP ➝ Motilal Oswal India Excellence Fund – Mid to Mega Series II 📌 Shares: 1,65,000 💵 Price: ₹988/share 💰 Transaction Value: ₹163.02 Million ➡️ Total transferred to Motilal Oswal Fund: 📊 5,05,000 shares | ₹498.94 Million 🔄 OTHER SECONDARY TRANSFERS 🔹 India Business Excellence Fund-II ➝ Satwani Holdings LLP 📌 1,97,244 shares @ ₹200 💰 ₹39.45 Million 🔹 Rosewood Investments ➝ Satwani Holdings LLP 📌 15,08,478 shares @ ₹200 💰 ₹301.69 Million 🔹 Mahendra Fuichand Sundesha ➝ Satwani Holdings LLP 📌 4,282 shares @ ₹200 💰 ₹0.86 Million 🔹 Narayanan Nathmar Safai jointly with Indra Saraf ➝ Satwani Holdings LLP 📌 2,340 shares @ ₹200 💰 ₹0.47 Million ➡️ Total: 📊 17,12,344 shares | ₹342.47 Million 📌 OVERALL SECONDARY TRANSFERS 🔥 Total Shares Transferred: 22,17,344 💰 Total Transaction Value: ₹841.41 Million 📅 Date: 17 August 2026 🏢 ABOUT SYMBIOTEC PHARMALAB Symbiotec Pharmalab Limited is a pharmaceutical company engaged in the development and manufacturing of pharmaceutical products. The company is preparing for its proposed public issue and has filed its DRHP with SEBI. 📢 IPOWATCH TAKE: The disclosed transactions provide an important look at pre-IPO secondary share activity and investor participation ahead of the proposed public issue. Investors should note that these transactions are secondary transfers and should not be interpreted as the IPO issue price or valuation. 🔔 Stay tuned with IPOWATCH for more Symbiotec Pharmalab IPO updates — including Anchor Allocation, Price Band, GMP, Subscription Status, Allotment & Listing Updates. ⚠️DISCLAIMER: This post is strictly for educational and informational purposes only and does not constitute investment advice, a recommendation, solicitation, or an offer to buy or sell any securities. Investors are advised to read the DRHP/RHP and other official documents carefully and consult a SEBI-registered investment adviser before making any investment decision. IPO investments are subject to market risks.

  • 🚨 AUGMONT ENTERPRISES IPO – ₹825 Cr IPO UPDATE! 📈🔥 One of the upcoming IPOs to watch this August! 👀 📅 IPO Dates: 21–25 August 2026 📌 Anchor Book: 20 August 2026 💰 Issue Size: ₹825 Cr 🔹 Fresh Issue: ₹620 Cr 🔹 OFS: ₹205 Cr 💵 Price Band: ₹750–₹788 📦 Lot Size: 19 Shares 💸 Retail Investment: ₹14,972 🪙 Face Value: ₹5 📊 IPO QUOTA 🔹 QIB: 50% (Anchor Included) 🔹 HNI: 15% 🔹 Retail: 35% 📱 Approx. Applications 👤 Retail: 1,91,925 💰 sHNI: 1,958 🏦 bHNI: 3,917 🏢 Market Cap ▪️ Pre-Issue: ₹6,580.23 Cr ▪️ Post-Issue: ₹7,200.23 Cr 👨‍💼 Promoter Holding: 92.75% ➝ 81.91% 📝 Registrar: MUFG Intime India Private Limited 📍 Listing: NSE & BSE 📅 KEY IPO DATES 🔹 Allotment: 27 August 2026 🔹 Refund/Unblocking: 28 August 2026 🔹 Demat Credit: 28 August 2026 🔹 Listing: 31 August 2026 🏢 ABOUT AUGMONT ENTERPRISES Augmont Enterprises is a player in India’s precious metals ecosystem, with a focus on gold and related bullion businesses. The company operates across the precious-metals value chain and serves customers through its business network. 📌 Stay tuned with IPOWATCH for the latest updates on Anchor Allocation, IPO Subscription Status, GMP, Allotment Status & Listing Updates. 🚀 ⚠️DISCLAIMER: This post is for educational and informational purposes only and should not be considered investment advice, a recommendation, or an offer to buy or sell securities. Investors should read the IPO’s RHP/DRHP and related official documents carefully and consult a SEBI-registered investment adviser before making any investment decision.

  • 15:013734

    Institutional Data for 17/08/2026 DII: 5101.46 Cr FII/FPI: -2535.10 Cr Net: 2566.36 Cr

  • 14:184052

    без подписи

  • без подписи

  • без подписи

  • 🚨IPO EVENTS OF THE DAY🚨 All eyes on today's key IPO updates - Don't miss it! 👀 📈

  • 🚨 TEMPSENS INSTRUMENTS IPO – FULL DETAILS 📈🔥 🌡️ Tempsens Instruments (India) Limited is set to launch its IPO from 20–24 August 2026. 💰 Issue Size: ₹650 Cr 🔹 Fresh Issue: ₹95 Cr 🔹 OFS: ₹555 Cr 💵 Price Band: ₹285–₹300 📦 Lot Size: 50 Shares 💸 Retail Investment: ₹15,000 🪙 Face Value: ₹4 📊 IPO QUOTA 🔹 QIB: 50% (Anchor Included) 🔹 HNI: 15% 🔹 Retail: 35% 👥 Approx. Applications 🔹 Retail: 1,51,317 🔹 sHNI: 1,544 🔹 bHNI: 3,088 🏢 Market Cap 🔹 Pre-Issue: ₹2,419.98 Cr 🔹 Post-Issue: ₹2,514.98 Cr 👨‍💼 Promoter Holding 80.51% ➝ 65.67% 📝 Registrar: KFin Technologies Limited 📍 Listing: NSE & BSE 📅 IMPORTANT DATES 🔸 Anchor Book: 19 Aug 2026 🔸 IPO Opens: 20 Aug 2026 🔸 IPO Closes: 24 Aug 2026 🔸 Allotment: 24 Aug 2026 🔸 Refund/Unblocking: 25 Aug 2026 🔸 Demat Credit: 26 Aug 2026 🔸 Listing: 27 Aug 2026 📲 Follow IPOWatch for IPO News, Review, Allotment & Analysis. ⚠️DISCLAIMER: This post is for educational and informational purposes only and should not be considered investment advice, a recommendation, or an offer/solicitation to buy or sell any securities. Investors should read the IPO offer documents carefully and consult a SEBI-registered investment adviser before making investment decisions.

  • *Big Breaking 🔥🔥* *NSE IPO Coming Soon 🔜* ▪️NSE is likely to launch its massive ₹29,000 Cr – ₹31,000 Cr IPO around mid-September this year, according to Mint. ▪️Retail Quota: 35% Potential Retail Applications: ~70 Lakhs 🔥

  • 🚨🥛 MILKY MIST IPO ALLOTMENT IS OUT! 🎉 📢 The much-awaited Milky Mist Dairy Food IPO Allotment has been announced! 🔍 Check your IPO allotment status now on IPOWatch 👇 👉 https://ipowatch.in/milky-mist-dairy-food-ipo-allotment-status/ ❤️ Got the allotment? Drop a ❤️ below!

  • без подписи

  • без подписи

  • 📊 IPO Subscription Update (Day 3 | 3:44 PM) 📊 Behari Lal Engineering IPO📈 🏦 QIB (Ex‑Anchor): 185.65x 💼 NII: 161.42x 👤 Retail: 47.96x ✅ Total: 105.09x 🧾 Total applications: 30,16,873 📈 Shares bid for: 71,54,67,792

  • 📊 IPO Subscription Update (Day 3 | 3:44 PM) 📊 Shiprocket IPO📈 🏦 QIB (Ex‑Anchor): 105.44x 💼 NII: 90.64x 👤 Retail: 43.60x 🧑‍💼 Employees: 54.60x ✅ Total: 90.12x 🧾 Total applications: 43,62,484 📈 Shares bid for: 8,27,01,10,310

  • 🏗️ Technocraft Ventures IPO Listed 📢 👉🏻 Listed at Rs 284 against the offer price of Rs 212 at Premium of +33.96% ⬆️

  • 🎬 Optimystix SME IPO Listed 📢 👉🏻 Listed at Rs 180 against the offer price of Rs 175 at Premium of +2.86% ⬆️

  • 📦 LEAP India IPO Listed 📢 👉🏻 Listed at Rs 165.90 against the offer price of Rs 159 at Premium of +4.34% ⬆️

  • без подписи

  • 🚨IPO EVENTS OF THE DAY🚨 All eyes on today's key IPO updates - Don't miss it! 👀 📈

  • 🚨 ZETWERK IPO UPDATE: ₹2,600 CRORE FRESH ISSUE! 🚀 🏭 Zetwerk Manufacturing Businesses Ltd has filed an Updated Draft Red Herring Prospectus (UDRHP) with SEBI for its proposed Mainboard IPO. 📌 KEY IPO DETAILS 💰 Fresh Issue: Up to ₹2,600 Cr 📦 OFS: Up to 96,837,455 Equity Shares 👥 Retail Quota: 10% 👨‍💼 Employee Reservation: Yes 💵 Face Value: ₹1 per share 🔄 Pre-IPO Placement: Up to ₹520 Cr — the Fresh Issue size will be reduced accordingly, if completed 🏦 BOOK RUNNING LEAD MANAGERS: • Kotak Mahindra Capital • Morgan Stanley • Goldman Sachs • Avendus Capital • JM Financial • HSBC Securities & Capital Markets • Pantomath Capital Advisors 🔥 Zetwerk IPO moves another step closer to the market! ⚠️DISCLAIMER: The UDRHP has been filed with SEBI. Filing of the UDRHP should not be construed as approval, recommendation or endorsement by SEBI. Investors are advised to read the UDRHP and all risk factors carefully before making any investment decision.